Key Market Indicator:
In this news category you will find information from and about companies, organizations, institutions, products of all kinds and in a broad spectrum. To get a quick overview of current trends and developments, it's worth visiting daily.
DE000A11QVV0
Thu, 09.09.2021       Heidelberg Pharma AG
DE000A11QVV0

PRESS RELEASE Heidelberg Pharma Announces Presentation at H.C. Wainwright 23rd Annual Global Investment Conference and Participation at Various Conferences Ladenburg, Germany, 9 September 2021 - Heidelberg Pharma AG (FSE: HPHA) today announced that they will present the company and its proprietary ATAC technology at several upcoming scientific a [ … ]
Technical analysis
To the publication
Tue, 07.09.2021       Heidelberg Pharma AG
DE000A11QVV0

  PRESS RELEASE Heidelberg Pharma provides update on Phase I/IIa clinical trial with ATAC candidate HDP-101 in the US - Compatibility tests for closed infusion system with HDP-101 successfully completed- Shipping of study medication to the US in preparation- Contract signed with first study center, MD Anderson Cancer Center; initiation of the ce [ … ]
Technical analysis
To the publication
Mon, 19.07.2021       Heidelberg Pharma AG
DE000A11QVV0

PRESS RELEASE Paul Ehrlich Institute Allows Heidelberg Pharma to Start a Phase I/IIa Clinical Trial with ATAC Candidate HDP-101 - Initiation of the first German study center planned within the next few months Ladenburg, Germany, 19 July 2021 - Heidelberg Pharma AG (FSE: HPHA) today announced that the German authority Paul Ehrlich Institute, Lang [ … ]
Technical analysis
To the publication
Thu, 08.07.2021       Heidelberg Pharma AG
DE000A11QVV0

PRESS RELEASE Heidelberg Pharma Reports on First Half-Year 2021 - HDP-101: Application to initiate clinical trial green-lighted by the FDA in February 2021; Clinical trial centers prepare to receive their first patient; Clinical Trial Application submitted to the Paul Ehrlich Institute in Germany - New preclinical data on the immunomodulatory po [ … ]
Technical analysis
To the publication
Thu, 17.06.2021       Heidelberg Pharma AG
DE000A11QVV0

PRESS RELEASE Heidelberg Pharma Announces Participation at Various Conferences Ladenburg, Germany, 17 June 2021 - Heidelberg Pharma AG (FSE: HPHA) today announced that they will present its proprietary ATAC technology at two upcoming scientific events. Heidelberg Pharma is an oncology specialist and the first company to develop the toxin Amaniti [ … ]
Technical analysis
To the publication
Tue, 18.05.2021       Heidelberg Pharma AG
DE000A11QVV0

PRESS RELEASE Annual General Meeting 2021 of Heidelberg Pharma Approves All Proposed Resolutions Ladenburg, Germany, 18 May 2021 - Heidelberg Pharma AG (FSE: HPHA) today announced that the shareholders of the Company approved the resolutions of the administration with large majorities (ranged from 98,40% to 99,99%) during the virtual Annual Gener [ … ]
Technical analysis
To the publication
Thu, 29.04.2021       Heidelberg Pharma AG
DE000A11QVV0

Heidelberg Pharma AG: Interim Management Statement on the First Three Months of 2021 - Application to initiate clinical trial of HDP-101 green-lighted by the FDA in February 2021 - Management team expanded - New financing commitment for up to EUR 30 million obtained from main shareholder dievini - New preclinical data from the ATAC technology plat [ … ]
Technical analysis
To the publication
Wed, 31.03.2021       Heidelberg Pharma AG
DE000A11QVV0

PRESS RELEASE Heidelberg Pharma to Present New Data on its Proprietary ATAC Technology Platform at the AACR Annual Meeting 2021 Ladenburg, Germany, 31 March 2021 - Heidelberg Pharma AG (FSE: HPHA) announced today that it will present preclinical data on its novel ATAC candidates HDP-102 and HDP-103 as well as data on synergistic effects of ATACs  [ … ]
Technical analysis
To the publication
Thu, 12.11.2020       Heidelberg Pharma AG
DE000A11QVV0

PRESS RELEASE Heidelberg Pharma will Present at German Equity Forum and Provides Update on Partner Activities for its Legacy Assets - RedHill Biopharma plans Phase II/III trial with upamostat in COVID-19 - Telix Pharmaceuticals enters into strategic license and commercial partnership for China with radio-labelled antibody girentuximab Ladenburg [ … ]
Technical analysis
To the publication
Thu, 05.11.2020       Heidelberg Pharma AG
DE000A11QVV0

PRESS RELEASE Heidelberg Pharma Announces Several Presentations of Research Results on ATAC Technology at the ASH Annual Meeting 2020 - Heidelberg Pharma presents the design for the planned clinical study with HDP-101 - Partner MD Anderson Cancer Center presents in an oral presentation preclinical data with HDP-101 on the induction of an immune  [ … ]
Technical analysis
To the publication

Gamechanger in online marketing · Innovation as a service · Upgrade your own internet presence.

Legend/Explanation
The newswire feed is updated several times a day. To make sure you don't miss any news, please check back here often. If you are curious about a headline or want to find out more about a publication, click on it to go to the preview and click again to go to the full news item.
Member of 3R/RSQ Network
Digital Content
Network Alliance
Transparency - Reliability - Credibility
Information regarding Product Information
Thursday, 04.07.2024, Calendar Week 27, 186th day of the year, 180 days remaining until EoY.